US Patent 10,214,509: Claim Scope, Nav1.7 Patent Strength and Generic Entry Risk

US Patent 10,214,509 protects a broad genus of substituted pyrazole, imidazole and 1,2,3-triazole carboxamides directed to voltage-gated sodium-channel modulation, particularly Nav1.7. Its strongest protection is concentrated in defined small-molecule structures and selected exemplified compounds. The patent does not, based on the supplied claims, establish protection for a marketed drug, dosage form, salt, formulation, or biologic.

The principal commercial risk is compound-level infringement. A competitor could face infringement exposure if its Nav1.7 inhibitor falls within Formula (I), even if it avoids the specifically listed compounds in claim 15. The broader genus claim is vulnerable to written-description, enablement, anticipation and obviousness attacks because it covers a very large chemical space with multiple heterocyclic cores and extensive substituent definitions.

What does US Patent 10,214,509 protect?

The patent claims chemical compounds, pharmaceutical compositions, combination products and therapeutic methods involving Nav1.7 modulation.

Claim group	Claims	Subject matter	Commercial relevance
Markush compound genus	1-13	Formula (I), salts, N-oxides and isotopically labeled derivatives	Primary composition-of-matter protection
Narrower chemical subgenera	2-14	Restrictions on R groups, ring nitrogens and substituent classes	Potential fallback positions during litigation or prosecution
Enumerated compounds	15	Large list of individually identified pyrazole, imidazole and triazole carboxamides	Stronger literal coverage for listed compounds
Pharmaceutical composition	16	Compound of claim 1 plus diluent or carrier	Conventional composition protection
Combination product	17	Compound plus broad classes of pain, respiratory, inflammatory and CNS agents	Secondary commercial protection
Treatment method	18-20	Treatment of Nav1.7-mediated disease, including pain, cough, itch, epilepsy and psychiatric disease	Use-based infringement and regulatory leverage

Claim 1 is the central claim. It covers a compound of Formula (I), or a pharmaceutically acceptable salt, N-oxide or isotopically labeled derivative, subject to a large set of structural variables.

The claim requires:

A nitrogen-containing heteroaromatic core defined by G1 and G2.
At least one ring nitrogen in that core.
A defined R2/R3 arrangement, including an anilide-type substituent or a fused nitrogen-containing group.
A second substituted aromatic or heteroaromatic region defined through R4, R5 and R6.
Broad substituent classes including halogens, alkyl groups, haloalkyl groups, alkoxy groups, cyano groups, sulfonamides, aryl groups, heteroaryl groups and amine-containing side chains.

The claim language is structurally broad rather than target-limited. A product does not need to be demonstrated to inhibit Nav1.7 to infringe claim 1 if its chemical structure falls within the claimed genus. Nav1.7 activity is principally relevant to claims 18-20 and to validity and written-description analysis.

How broad is claim 1 of US 10,214,509?

Claim 1 is a large Markush claim with multiple independent structural decision points. Its breadth comes from both ring-system alternatives and substituent breadth.

Core heterocycle coverage

The claim permits:

G1 as nitrogen or carbon;
G2 as nitrogen or substituted carbon;
at least one nitrogen among G1 and G2.

This allows more than one heteroaromatic core arrangement. The dependent claims separately emphasize:

A diazine-like arrangement in claim 9;
A nitrogen-carbon arrangement in claim 10;
Additional ring restrictions in claims 3, 5 and 6.

The claim therefore reaches a family of related heterocycles rather than a single scaffold.

R2 and R3 architecture

Claim 1 covers two principal arrangements:

R2 is hydrogen and R3 is Formula (i), which appears to define a substituted heteroaryl or related aromatic ring system.
R2 and R3 jointly form Formula (ii), a nitrogen-containing fused or cyclic structure.

Claims 4-6 narrow the Formula (i) branch by limiting G3 and R7. These claims are materially more defensible than the unconstrained portion of claim 1 because they reduce the number of possible ring and substituent combinations.

R4 substituent breadth

R4 is particularly expansive. It includes:

Halogen and hydroxyl;
C1-C4 alkyl and haloalkyl;
Alkoxyalkyl and alkylalkoxy groups;
Aryl and heteroaryl groups;
Saturated and unsaturated heterocycles;
Amino, alkylamino and dialkylamino substituents;
Sulfonamide groups;
Carbamoylmethyl and related oxygen-linked amide substituents.

This scope captures the medicinal-chemistry optimization space around the claimed scaffold. It also creates the largest validity pressure. A court or Patent Trial and Appeal Board would likely focus on whether the specification provides adequate representative support across the full range of R4 alternatives.

R6 substituent breadth

R6 covers:

Halogen;
Cyano;
C1-C4 alkyl;
Haloalkyl and haloalkoxy;
Trifluoromethylsulfonyl;
Phenoxy;
Benzyl;
Benzyloxy.

Claims 2, 7 and 8 narrow R6, with claim 8 selecting chlorine, bromine, methyl, ethyl or trifluoromethyl. These narrowed versions are likely more commercially relevant because many drug-like exemplified molecules use those substituents.

What compounds are specifically protected?

Claim 15 lists a very large number of compounds. The listed structures share recurring pharmacophoric elements:

A 5-amino pyrazole-4-carboxamide core;
An N-substituted aromatic or heteroaromatic ring;
Frequent use of 5-chloropyridin-2-yl or 5-trifluoromethylpyridin-2-yl amide substituents;
Ortho-substituted phenyl groups, including methyl, methoxy, fluoro, chloro, bromo and 2-methoxyethoxy substituents;
3-methyl and 3-ethyl pyrazole variants;
Pyridyl, oxazolyl, pyrazolyl and other heteroaryl extensions;
Basic side chains such as dimethylaminomethyl, pyrrolidinylmethyl, morpholinomethyl and piperidinyl derivatives;
Amide, ether, hydroxyalkoxy and sulfonamide substituents;
Selected imidazole and 1,2,3-triazole analogues.

The enumerated list is important because a specifically disclosed and claimed compound generally has a clearer infringement path than a remote member of a broad Markush genus. Claim 15 also creates a set of potential fallback positions if claim 1 is narrowed or invalidated.

The proviso in claim 1 excludes ten earlier compounds, principally simple 5-amino-1-aryl-1,2,3-triazole-4-carboxamides. Those exclusions appear designed to distinguish the claimed genus from known compounds and to reduce anticipation risk. They do not materially eliminate the broader infringement risk for structurally adjacent compounds.

How strong is the composition-of-matter protection?

Strengths

The composition claims have several features favorable to the patent owner:

Claim 1 covers the active chemical entity rather than only a treatment method.
The claim expressly includes pharmaceutically acceptable salts, N-oxides and isotopically labeled derivatives.
Claims 14 and 15 provide narrower structural positions.
The claim set includes multiple heterocyclic cores and extensive substitution patterns.
The patent appears designed to cover a medicinal-chemistry series rather than one isolated lead compound.

A valid composition claim can block a competitor irrespective of the competitor's manufacturing process, formulation, indication or dose.

Weaknesses

The same breadth creates significant validity risks.

Written description

Under 35 U.S.C. §112(a), the specification must show possession of the claimed invention across the scope of the claim. A claim covering multiple ring systems, dozens of substituent classes and numerous heterocycle combinations may be attacked as broader than the disclosed representative compounds.

The risk is greatest for:

Rare combinations of G1/G2 and G3/G4;
Broad R4 side-chain classes with few examples;
N-oxide and isotopically labeled derivatives;
Compounds using less frequently exemplified heteroaryl and saturated heterocyclic substituents;
Combinations that were not specifically synthesized or tested.

Enablement

The patent owner must show that the full claimed genus can be made and used without undue experimentation. The large number of possible compounds, stereochemical variants, salts and substitution patterns could support an enablement challenge under the post-Amgen v. Sanofi framework, particularly if the patent provides limited biological data across the genus. [2]

Anticipation

Anticipation risk is likely lower for the specifically listed compounds than for the broad genus. The claim's express exclusions indicate that the applicant addressed known triazole-carboxamide prior art. A challenger would still examine:

Earlier pyrazole carboxamides;
Nav1.7 inhibitor disclosures;
Patent families from Xenon, Genentech, Vertex, Grünenthal and other sodium-channel programs;
Combinatorial medicinal-chemistry disclosures containing overlapping Markush definitions;
Published applications with overlapping core structures.

Obviousness

The broad claim may face a stronger obviousness challenge than the individual compounds. A challenger could argue that the claimed scaffold was an obvious variation of known sodium-channel modulators and that routine substitution would have produced the claimed analogues.

The patent owner's best response would be unexpected activity, selectivity for Nav1.7 over other sodium-channel subtypes, improved pharmacokinetics, oral exposure, reduced CNS penetration or efficacy in relevant pain or cough models. The supplied claims do not provide those data.

What do claims 16-20 add?

Pharmaceutical composition claim 16

Claim 16 covers a composition containing a claim 1 compound and a pharmaceutically acceptable diluent or carrier. This is a conventional formulation claim with limited incremental strength.

It may be useful against a finished pharmaceutical product, but it does not claim:

A particular tablet or capsule;
A specific release profile;
A defined particle size;
A particular polymorph;
A crystalline form;
A specific excipient system;
A dose or dosing schedule;
A pharmaceutical composition limited to a clinical indication.

As a result, claim 16 is unlikely to provide meaningful independent protection if claim 1 is invalid or does not cover the accused compound.

Combination claim 17

Claim 17 covers combinations with extensive therapeutic classes, including opioids, NSAIDs, COX-2 inhibitors, ion-channel modulators, anti-inflammatory agents, JAK inhibitors, respiratory agents, antipruritics and proton-pump inhibitors.

The claim is commercially broad but legally exposed. Potential issues include:

Lack of demonstrated synergy across the many listed classes;
Written-description support for all combinations;
Enablement of every combination;
Functional treatment limitations;
Obviousness based on combination therapy practices.

This claim may have value for a marketed coformulation or combination regimen, but only if the partner drug and method of use are within the claim's interpretation.

Method claims 18-20

Claims 18-20 cover treating disease mediated by voltage-gated sodium channels, particularly Nav1.7. The listed conditions include:

Acute and chronic pain;
Neuropathic, inflammatory, visceral and nociceptive pain;
Diabetic neuropathy and postherpetic neuralgia;
Migraine and cancer pain;
Chronic cough and respiratory disease;
Itch and dermatological disease;
Epilepsy;
Schizophrenia and bipolar disorder.

The method claims are broad and span unrelated disease categories. That breadth may create written-description and enablement issues if the specification does not show activity in each category.

Method claims also require proof that the accused product is used for the claimed purpose. A generic manufacturer may reduce risk by labeling the product for an indication outside the claimed uses, although induced-infringement exposure can still arise from promotional materials, clinical instructions, prescribing behavior or foreseeable use.

When does US Patent 10,214,509 lose exclusivity?

The patent's enforceable term depends on its earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers and any applicable patent-term extension. A patent generally expires 20 years from the earliest effective nonprovisional filing date under 35 U.S.C. §154, subject to those adjustments. [3]

The patent number and claim text alone do not establish a reliable expiration date. The controlling analysis requires the patent's front-page priority data, continuity statements and USPTO term calculation.

The following dates must be distinguished:

Date	Legal significance
Earliest priority date	Determines priority and may affect prior-art entitlement
PCT or nonprovisional filing date	Relevant to the 20-year patent term
US national-stage date	Does not automatically determine the full term
Issue date	Does not ordinarily determine expiration
Patent-term adjustment	Adds USPTO delay days
Patent-term extension	May extend a qualifying product patent after FDA approval
Terminal disclaimer	Can shorten the term to that of another patent

There is no indication in the supplied claims that the patent has FDA-linked patent-term extension. Because no approved drug is identified, an Orange Book patent-term extension analysis cannot be completed from the claim text.

What is the Orange Book status of US Patent 10,214,509?

The supplied information does not establish an Orange Book listing. Orange Book listing depends on an approved NDA and a patent submitted by the NDA holder for a drug substance, drug product, method of use or other qualifying subject matter. [4]

A patent directed to an experimental Nav1.7 chemical series is not automatically listed. If no product incorporating a claim 1 compound has FDA approval, the patent would not create an Orange Book-based ANDA stay or Paragraph IV litigation pathway.

The relevant distinction is:

An Orange Book-listed drug substance patent can support a Paragraph IV challenge against an ANDA.
A non-listed research patent can still support ordinary patent litigation against commercial manufacture, sale or use.
A method-of-use patent may be listed only where it meets FDA listing requirements and corresponds to an approved labeling indication.
A patent covering an unapproved compound has no automatic Hatch-Waxman exclusivity effect.

Are Paragraph IV challenges or generic entry currently implicated?

No Paragraph IV challenge can be inferred from the claim text. A Paragraph IV case requires an ANDA applicant, an identified reference-listed drug and an Orange Book patent listing. [5]

If a claim 1 compound later becomes an approved active pharmaceutical ingredient, generic entry could follow several paths:

Entry route	Required facts	Relevance to this patent
Paragraph IV ANDA	Listed drug and patent; applicant certifies invalidity, unenforceability or noninfringement	Potentially relevant only after an approved product and listing
Section VIII carve-out	Generic omits patented indication	Relevant to claims 19-20 if those indications are listed
505(b)(2) application	Relies partly on FDA findings for an approved product	May face composition and method patents
Ordinary commercial launch	Product is not an ANDA generic or is sold for research use	Exposed primarily to direct infringement claims
Post-expiry launch	Patent term has ended	Requires verified term calculation

The highest-risk generic scenario would involve an ANDA product containing the same active compound or a salt within claim 1, with a label covering Nav1.7-mediated pain, cough or itch. A noninfringing-design scenario would require a compound outside the literal structural boundaries of claim 1 and outside any valid doctrine-of-equivalents theory.

What formulation patents are protected?

The supplied claims do not contain a meaningful formulation patent estate. Claim 16 covers a compound plus a conventional carrier or diluent. It does not protect a differentiated formulation technology.

There are no supplied claims directed to:

Extended release;
Immediate release with defined dissolution;
Transdermal delivery;
Inhaled delivery;
Injectable delivery;
Long-acting depot formulations;
Nanoparticles or liposomes;
Solid dispersions;
Amorphous or crystalline forms;
Polymorphs;
Specific salt forms;
Co-crystals;
Particle-size distributions;
Stability or packaging systems.

A commercial product based on a claim 1 compound would therefore require a separate search for formulation, polymorph, salt, process and manufacturing patents.

What manufacturing and process barriers exist?

The claims are principally product claims. They do not, in the supplied text, claim:

A specific synthetic route;
A process intermediate;
A catalyst;
A crystallization method;
A purification process;
A polymorph;
A manufacturing specification.

A competitor that makes a covered compound through a different process may still infringe claim 1. Conversely, a process patent held by the same or another party could create an independent manufacturing barrier.

The chemistry likely involves substituted aromatic or heteroaromatic intermediates and amide formation. Commercial risk may arise from:

Supply of halogenated heteroaryl intermediates;
Control of regioisomers;
Purification of closely related analogues;
Salt selection;
Scale-up of heteroaryl coupling reactions;
Control of residual catalysts and genotoxic impurities;
Stereochemical control for compounds containing chiral side chains.

Those issues are technical barriers, not necessarily barriers created by US Patent 10,214,509.

How does this patent compare with competing Nav1.7 patent estates?

The patent occupies the small-molecule Nav1.7 inhibitor field but does not, from the supplied claims, identify a target-selective clinical candidate or a known marketed product.

Estate type	Typical protection	Relative position of US 10,214,509
Broad Nav1.7 chemical genus	Large Markush compounds	Comparable in breadth
Named clinical candidate	Specific active compound	US 10,214,509 may be stronger if the candidate falls within claim 15
Selectivity patent	Nav1.7 over Nav1.1, Nav1.5 or Nav1.6	Not apparent from supplied claims
Formulation estate	Release profile, salt, polymorph or delivery system	Not apparent
Method-of-use estate	Pain, cough, itch or neuropathy	Claims 18-20 provide broad method coverage
Manufacturing estate	Process and intermediate claims	Not apparent
Biologic or antibody estate	Antibody, antisense or gene therapy	Not relevant to this small-molecule patent

The principal competitive question is whether a rival Nav1.7 program uses a compound inside the Formula (I) genus. Target overlap alone is insufficient. Two companies can pursue Nav1.7 with chemically distinct compounds and avoid literal infringement.

Which companies could create competitive or litigation pressure?

The Nav1.7 field has included programs from companies such as Xenon Pharmaceuticals, Vertex Pharmaceuticals, Genentech, Grünenthal, Pfizer and other pharmaceutical and biotechnology developers. Competitive relevance depends on the specific compound and patent family, not merely participation in the target class.

The most important third-party searches would cover:

Patent families claiming Nav1.7-selective small molecules;
Priority dates before the effective filing date of US 10,214,509;
Overlapping pyrazole, imidazole and triazole carboxamides;
Patent citations and cited-by documents;
PCT national-stage members;
Continuations and divisionals;
Assignments and licenses;
Inter partes review petitions;
District-court infringement cases;
FDA approval and Orange Book records for any compound within the claims.

No licensing deal, assignment, Paragraph IV action, settlement or litigation outcome is established by the supplied claim text.

What geographic coverage does the patent provide?

US Patent 10,214,509 provides US territorial rights only. International protection would depend on corresponding national or regional family members.

Potential family jurisdictions could include:

Europe through the EPO;
Japan;
China;
Canada;
Australia;
South Korea;
India;
Brazil.

Foreign claim scope may differ materially because of:

Added-matter standards;
Support and enablement requirements;
Unity objections;
National examination amendments;
Patent-term rules;
Divisional practice;
Method-of-treatment exclusions;
Supplementary protection certificate eligibility.

A US freedom-to-operate conclusion cannot be extended to Europe, China or other jurisdictions without reviewing the corresponding family members.

What generic launch risks exist?

The risk profile depends on the identity of the accused compound.

High-risk product

A product is high risk if it:

Is one of the compounds expressly listed in claim 15;
Falls within claim 14's narrowed Formula (II);
Uses a 5-amino pyrazole-4-carboxamide with the recurring substituted pyridyl amide motif;
Contains a permitted R6 halogen, methyl, ethyl or trifluoromethyl group;
Is marketed for Nav1.7-mediated pain, cough or itch;
Is supplied as a salt, N-oxide or isotope derivative of a covered compound.

Moderate-risk product

Risk is moderate if the compound:

Falls within the broad Markush language but is remote from the examples;
Uses an unusual R4 heterocycle or side chain;
Has uncertain ring assignment under Formula (I);
Is used for a non-listed indication;
Is not an approved drug subject to Orange Book listing.

Lower-risk product

Risk is lower if the compound:

Clearly falls outside the G1/G2 nitrogen requirement;
Uses a core not covered by Formula (I);
Has an excluded or structurally distinct amide arrangement;
Does not meet the R2/R3 connection requirements;
Is made and sold outside the United States;
Is used only in a manner that does not satisfy claims 18-20.

Key Takeaways

US Patent 10,214,509 is primarily a compound patent for substituted pyrazole, imidazole and 1,2,3-triazole carboxamides associated with Nav1.7 modulation.
Claim 1 is broad and creates meaningful composition-of-matter risk for structurally related Nav1.7 inhibitors.
Claim 15 is commercially important because it identifies a large number of specific compounds with clearer literal coverage.
Claims 16 and 17 provide limited incremental strength compared with the compound claims.
Claims 18-20 cover broad therapeutic uses, including pain, cough, itch, epilepsy and psychiatric disorders, but may face written-description and enablement challenges.
The patent does not, from the supplied claims, establish a differentiated formulation, polymorph, salt, process or manufacturing estate.
No Orange Book listing, Paragraph IV challenge, litigation, settlement, license or FDA approval can be established from the claim text.
Patent expiration requires verified priority, continuity, patent-term adjustment and terminal-disclaimer data.
Generic or competitor risk turns on the exact structure of the proposed product, not merely its Nav1.7 mechanism.
The broadest validity pressure is likely to focus on written description, enablement, anticipation and obviousness under 35 U.S.C. §§102, 103 and 112.

FAQs

Does US Patent 10,214,509 cover all Nav1.7 inhibitors?

No. It covers compounds meeting the structural limitations of Formula (I), plus specified compositions, combinations and treatment methods. A Nav1.7 inhibitor with a different scaffold may fall outside the claims.

Can a different salt avoid US Patent 10,214,509?

Usually not if the underlying active compound falls within claim 1. Claim 1 expressly includes pharmaceutically acceptable salts.

Does claim 15 provide stronger protection than claim 1?

Often yes. A specifically named compound generally presents a clearer literal-infringement case than a remote compound alleged to fall within a broad Markush genus.

Can a generic company use a Section VIII carve-out to avoid these claims?

Possibly, but only if the relevant patent is Orange Book listed for a particular method of use and the generic label successfully omits that patented indication. A carve-out does not avoid a valid compound claim.

Does the patent block use of unrelated Nav1.7 biologics?

No. The supplied claims are directed to small molecules, pharmaceutical compositions, combinations and treatment methods involving the claimed compounds. They do not claim antibodies, antisense agents, gene therapies or other biologic Nav1.7 modalities.

References

United States Patent No. 10,214,509, claims 1-20 (2019).
Amgen Inc. v. Sanofi, 598 U.S. 594 (2023).
35 U.S.C. §154.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.
21 U.S.C. §355(j)(2)(A)(vii)(IV); 35 U.S.C. §271(e)(2).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	13-Mar-24	⤷ Start Trial	2036-04-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Summary for Patent: 10,214,509